Characteristics and symptoms of patients and staff members with norovirus gastroenteritis
| . | Patients (n = 11) . | Staff members (n = 11) . | P . |
|---|---|---|---|
| Median age, y (range) | 56 (17-71) | 38 (20-56) | .045 |
| Sex, male/female | 4/7 | 4/7 | ns |
| Secretor status | |||
| Se/se | 7 | nd | |
| Se/Se | 4 | nd | |
| Underlying diseases | |||
| Acute leukemia | 5 | ||
| Lymphoma | 6 | ||
| Therapy | |||
| Rituximab monotherapy | 1 | ||
| Chemotherapy | 5 | ||
| Autologous HSCT | 2 | ||
| Allogeneic HSCT | 3 | ||
| First symptoms after chemotherapy (n = 5) median days (range) | 19 (4-56) | ||
| First symptoms relative to HSCT (n = 5), median days (range) | 71 (−6 to 210) | ||
| Neutrophils, < 500/μL* | 7 | ||
| Symptoms, median days (range) | 7 (2-36) | 3 (1-13) | .02 |
| Nausea | 4 | 9 | ns |
| Vomiting | 8 | 7 | ns |
| Diarrhea | 11 | 9 | ns |
| Fever (≥ 38.5°C) | 6 | 1 | ns |
| Complications | |||
| Fatal aspiration | 1 | ||
| Septicemia | 2 |
| . | Patients (n = 11) . | Staff members (n = 11) . | P . |
|---|---|---|---|
| Median age, y (range) | 56 (17-71) | 38 (20-56) | .045 |
| Sex, male/female | 4/7 | 4/7 | ns |
| Secretor status | |||
| Se/se | 7 | nd | |
| Se/Se | 4 | nd | |
| Underlying diseases | |||
| Acute leukemia | 5 | ||
| Lymphoma | 6 | ||
| Therapy | |||
| Rituximab monotherapy | 1 | ||
| Chemotherapy | 5 | ||
| Autologous HSCT | 2 | ||
| Allogeneic HSCT | 3 | ||
| First symptoms after chemotherapy (n = 5) median days (range) | 19 (4-56) | ||
| First symptoms relative to HSCT (n = 5), median days (range) | 71 (−6 to 210) | ||
| Neutrophils, < 500/μL* | 7 | ||
| Symptoms, median days (range) | 7 (2-36) | 3 (1-13) | .02 |
| Nausea | 4 | 9 | ns |
| Vomiting | 8 | 7 | ns |
| Diarrhea | 11 | 9 | ns |
| Fever (≥ 38.5°C) | 6 | 1 | ns |
| Complications | |||
| Fatal aspiration | 1 | ||
| Septicemia | 2 |
Numbers of patients are given, if not stated otherwise.
nd indicates not determined; and ns, not significant.
At onset of symptoms.